Recent CYTK News
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:17:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:05:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:04:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:03:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:01:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 10:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/16/2024 09:59:41 PM
- Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024 • GlobeNewswire Inc. • 05/15/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:09:19 PM
- Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine • GlobeNewswire Inc. • 05/13/2024 01:33:00 PM
- Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 05/13/2024 01:33:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:05:52 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 08:05:16 PM
- Cytokinetics Reports First Quarter 2024 Financial Results • GlobeNewswire Inc. • 05/08/2024 08:00:00 PM
- Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586 • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy • GlobeNewswire Inc. • 05/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:05:11 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/08/2024 11:00:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/07/2024 08:37:54 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 05/07/2024 08:35:51 PM
- Cytokinetics to Hold Annual Meeting of Stockholders • GlobeNewswire Inc. • 05/07/2024 08:00:00 PM
- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 05/02/2024 08:00:00 PM
- Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 04/29/2024 08:00:00 PM
- Cytokinetics to Announce First Quarter Results on May 8, 2024 • GlobeNewswire Inc. • 04/24/2024 08:00:00 PM
- Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress • GlobeNewswire Inc. • 04/10/2024 11:30:00 AM
FEATURED Cannabix Technologies and Omega Laboratories Inc. enter Strategic Partnership to Commercialize Marijuana Breathalyzer Technology • May 16, 2024 8:13 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM
Avant Technologies to Revolutionize Data Center Management with Proprietary AI Software Platform • AVAI • May 16, 2024 8:00 AM
HealthLynked Corp Announces First Quarter 2024 Results: Achieves 8% Revenue Growth Over Last Quarter • HLYK • May 16, 2024 8:00 AM
Integrated Ventures Files Q3/2024 With Mining Revenues Of $1,983,250 And Positive Earnings Of $0.05 Cents Per Share • INTV • May 15, 2024 10:30 AM
Swifty Global Announces Impressive Financial Results for Q1 2024 • DRCR • May 15, 2024 10:25 AM